PriceTargets.com logo

Horizon Therapeutics Public - HZNP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$116.30 As of 10/6/2023 01:00 AM ET
+0 (0.00%)
Get New Horizon Therapeutics Public Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HZNP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HZNP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Horizon Therapeutics Public in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $116.30.

This chart shows the closing price for HZNP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Horizon Therapeutics Public. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2023Jefferies Financial GroupDowngradeBuy ➝ HoldLow
12/13/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$88.00 ➝ $116.50Low
12/13/2022BMO Capital MarketsDowngradeOutperform ➝ Market PerformLow
12/13/2022GuggenheimDowngradeBuy ➝ Neutral$98.00 ➝ $116.50Low
12/12/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$118.00 ➝ $116.50Low
12/12/2022Piper SandlerDowngradeOverweight ➝ NeutralLow
12/12/2022Stifel NicolausDowngradeBuy ➝ Hold$138.00 ➝ $116.50Low
12/7/2022Piper SandlerBoost TargetOverweight$90.00 ➝ $110.00Low
12/1/2022Jefferies Financial GroupBoost Target$101.00 ➝ $125.00Low
11/3/2022SVB LeerinkBoost TargetOutperform$80.00 ➝ $88.00Low
11/1/2022HC WainwrightInitiated CoverageNeutral$74.00Low
10/25/2022Piper SandlerLower TargetOverweight$90.00 ➝ $88.00Low
8/4/2022SVB LeerinkDowngradeOutperform ➝ Market PerformLow
8/4/2022The Goldman Sachs GroupLower TargetBuy$164.00 ➝ $144.00Low
8/4/2022Morgan StanleyLower TargetOverweight$135.00 ➝ $90.00N/A
8/4/2022BMO Capital MarketsLower TargetOutperform$145.00 ➝ $117.00Low
8/4/2022UBS GroupDowngradeBuy ➝ Neutral$137.00 ➝ $71.00Low
7/8/2022OppenheimerReiterated RatingBuy$140.00N/A
7/5/2022UBS GroupLower TargetBuy$139.00 ➝ $137.00N/A
6/13/2022UBS GroupInitiated CoverageBuy$139.00Low
5/23/2022SVB LeerinkInitiated CoverageMarket Perform$95.00High
4/8/2022Wells Fargo & CompanyReiterated RatingBuy$133.00Low
3/25/2022Wells Fargo & CompanyReiterated RatingBuy$133.00Low
3/14/2022OppenheimerInitiated CoverageOutperform$140.00Medium
3/2/2022Morgan StanleyBoost TargetOverweight$135.00 ➝ $140.00Low
1/26/2022Piper SandlerLower Target$143.00 ➝ $133.00Low
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$137.00Low
11/18/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy$168.00Low
10/13/2021Jefferies Financial GroupInitiated CoverageBuy$132.00Low
8/26/2021Morgan StanleyBoost TargetOverweight$103.00 ➝ $135.00Low
8/24/2021The Goldman Sachs GroupBoost TargetNeutral$96.00 ➝ $107.00Low
8/5/2021BMO Capital MarketsBoost TargetOutperform$118.00 ➝ $132.00Low
8/5/2021CitigroupBoost TargetBuy$117.00 ➝ $121.00Medium
5/27/2021Maxim GroupReiterated RatingReduceHigh
3/29/2021Morgan StanleyReiterated RatingOverweight$103.00High
3/25/2021GuggenheimBoost TargetBuy$115.00 ➝ $120.00Low
3/22/2021Morgan StanleyInitiated CoverageOverweight$103.00Medium
3/19/2021Jefferies Financial GroupReiterated RatingBuy$120.00Low
3/18/2021CitigroupBoost Target$116.00 ➝ $120.00High
3/17/2021Stifel NicolausBoost TargetBuy$110.00 ➝ $125.00High
3/11/2021Wolfe ResearchInitiated CoverageOutperform$107.00Low
2/17/2021Jefferies Financial GroupBoost Target$103.00 ➝ $120.00Low
2/9/2021Bank of AmericaReiterated RatingBuy$100.00Low
11/3/2020BMO Capital MarketsBoost TargetOutperform$105.00 ➝ $110.00Medium
9/9/2020JPMorgan Chase & Co.Initiated CoverageOverweight$110.00High
8/27/2020CitigroupInitiated CoverageBuy$112.00Medium
8/17/2020Bank of AmericaBoost TargetBuy$92.00 ➝ $95.00Low
8/10/2020Morgan StanleyBoost TargetOverweight$70.00 ➝ $90.00Low
8/6/2020GuggenheimBoost Target$64.00 ➝ $100.00High
8/6/2020BMO Capital MarketsBoost TargetOutperform$70.00 ➝ $105.00High
8/3/2020Stifel NicolausBoost Target$60.00 ➝ $85.00Low
7/31/2020Morgan StanleyBoost TargetOverweight$50.00 ➝ $70.00Low
7/22/2020Piper SandlerBoost TargetOverweight$61.00 ➝ $90.00Low
7/16/2020GuggenheimBoost Target$50.00 ➝ $64.00Low
6/5/2020Piper SandlerReiterated RatingBuy$61.00Medium
5/29/2020Stifel NicolausBoost Target$50.00 ➝ $60.00High
5/26/2020Bank of AmericaBoost TargetBuy$52.00 ➝ $57.00Medium
5/21/2020Piper SandlerBoost TargetOverweight$50.00 ➝ $61.00Medium
5/8/2020Morgan StanleyBoost TargetOverweight$39.00 ➝ $50.00High
4/28/2020Jefferies Financial GroupBoost TargetBuy$47.00 ➝ $51.00High
4/14/2020Piper SandlerLower TargetOverweight$46.00 ➝ $44.00High
4/8/2020Stifel NicolausReiterated RatingBuy$45.00Low
4/2/2020Morgan StanleyLower TargetOverweight$42.00 ➝ $39.00High
3/23/2020Bank of AmericaLower TargetBuy$45.00 ➝ $42.00Low
2/25/2020Bank of AmericaReiterated RatingBuy$45.00High
1/22/2020BMO Capital MarketsBoost TargetOutperform$40.00 ➝ $46.00Low
1/14/2020JMP SecuritiesBoost TargetOutperform$47.00Medium
1/8/2020The Goldman Sachs GroupInitiated CoverageNeutral$35.00Low
12/24/2019Piper Sandler CompaniesReiterated RatingBuy$36.00 ➝ $49.00Low
12/16/2019Morgan StanleyBoost TargetOverweight$32.00 ➝ $38.00High
12/16/2019Jefferies Financial GroupBoost TargetBuy$35.00 ➝ $40.00High
12/16/2019Stifel NicolausBoost TargetBuy$35.00 ➝ $40.00High
12/16/2019BMO Capital MarketsBoost TargetOutperform$36.00 ➝ $40.00High
11/8/2019Cantor FitzgeraldBoost TargetOverweight$32.00 ➝ $36.00Low
9/26/2019Bank of AmericaInitiated CoverageBuy$34.00High
9/13/2019Stifel NicolausSet TargetBuy$35.00Low
9/12/2019GuggenheimInitiated CoverageBuy$36.00Low
8/26/2019Piper Sandler CompaniesSet TargetBuy$33.00Low
8/14/2019BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$29.00 ➝ $36.00Low
8/7/2019CowenSet TargetBuy$35.00Medium
5/8/2019MizuhoSet TargetHold$27.00Low
5/1/2019CitigroupUpgradeNeutral ➝ Buy$21.00 ➝ $32.00Medium
(Data available from 4/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 8 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Horizon Therapeutics Public logo
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $116.30
Low: $116.30
High: $116.30

50 Day Range

MA: $115.72
Low: $112.60
High: $116.30

52 Week Range

Now: $116.30
Low: $60.03
High: $116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?

The following Wall Street analysts have issued reports on Horizon Therapeutics Public in the last twelve months: Jefferies Financial Group Inc., StockNews.com, and TheStreet.
View the latest analyst ratings for HZNP.

What is the current price target for Horizon Therapeutics Public?

0 Wall Street analysts have set twelve-month price targets for Horizon Therapeutics Public in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Horizon Therapeutics Public in the next year.
View the latest price targets for HZNP.

What is the current consensus analyst rating for Horizon Therapeutics Public?

Horizon Therapeutics Public currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HZNP, but not buy more shares or sell existing shares.
View the latest ratings for HZNP.

What other companies compete with Horizon Therapeutics Public?

Other companies that are similar to Horizon Therapeutics Public include Royalty Pharma, Alexion Pharmaceuticals, MyoKardia, Jazz Pharmaceuticals and Elanco Animal Health. Learn More about companies similar to Horizon Therapeutics Public.

How do I contact Horizon Therapeutics Public's investor relations team?

Horizon Therapeutics Public's physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company's listed phone number is (531) 772-2100 and its investor relations email address is [email protected]. The official website for Horizon Therapeutics Public is www.horizontherapeutics.com. Learn More about contacing Horizon Therapeutics Public investor relations.